The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series
Introduction: Pediatric-onset multiple sclerosis (POMS) is characterized by high inflammatory disease activity. Our aim was to describe the treatment sequencing and report the impact highly effective disease-modifying treatment (HET) had on disease activity. Materials and Methods: Five consecutive p...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/9/11/1698 |
| _version_ | 1797468673316749312 |
|---|---|
| author | Paolo Immovilli Paola De Mitri Veronica Bazzurri Stefano Vollaro Nicola Morelli Giacomo Biasucci Fabiola Magnifico Elena Marchesi Maria Lara Lombardelli Lorenza Gelati Donata Guidetti |
| author_facet | Paolo Immovilli Paola De Mitri Veronica Bazzurri Stefano Vollaro Nicola Morelli Giacomo Biasucci Fabiola Magnifico Elena Marchesi Maria Lara Lombardelli Lorenza Gelati Donata Guidetti |
| author_sort | Paolo Immovilli |
| collection | DOAJ |
| description | Introduction: Pediatric-onset multiple sclerosis (POMS) is characterized by high inflammatory disease activity. Our aim was to describe the treatment sequencing and report the impact highly effective disease-modifying treatment (HET) had on disease activity. Materials and Methods: Five consecutive patients with POMS were administered HET following lower efficacy drug or as initial therapy. Data on treatment sequencing, relapses and MRIs were collected during the follow-up. Results: Our patients had an average age of 13.8 years (range 9–17) at diagnosis and 13.4 years (range 9–16) at disease onset, and 2/5 (40%) POMS were female. The pre-treatment average annualized relapse rate was 1.6 (range 0.8–2.8), and the average follow-up length was 5 years (range 3–7). A total of 2/5 (40%) patients were stable on HET at initial therapy, and 3/5 (60%) required an escalation to more aggressive treatment, even if two of them had been put on HET as initial treatment. Four out of five patients (80%) had No Evidence of Disease Activity-3 status (NEDA-3) at an average follow-up of 3 years (range 2–5). Conclusion: It has been observed that in a recent time period all the cases had prompt diagnosis, early HET or escalation to HET with a good outcome in 80% of the cases. |
| first_indexed | 2024-03-09T19:10:45Z |
| format | Article |
| id | doaj.art-dcf513d86dd84b3088eda2a093b37e96 |
| institution | Directory Open Access Journal |
| issn | 2227-9067 |
| language | English |
| last_indexed | 2024-03-09T19:10:45Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Children |
| spelling | doaj.art-dcf513d86dd84b3088eda2a093b37e962023-11-24T04:12:23ZengMDPI AGChildren2227-90672022-11-01911169810.3390/children9111698The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case SeriesPaolo Immovilli0Paola De Mitri1Veronica Bazzurri2Stefano Vollaro3Nicola Morelli4Giacomo Biasucci5Fabiola Magnifico6Elena Marchesi7Maria Lara Lombardelli8Lorenza Gelati9Donata Guidetti10The Neurology Unit, Emergency Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyThe Neurology Unit, Emergency Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyThe Neurology Unit, Emergency Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyThe Neurology Unit, Emergency Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyThe Neurology Unit, Emergency Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyThe Pediatric Unit, Maternal and Child Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyThe Neurology Unit, Emergency Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyThe Neurology Unit, Emergency Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyThe Neurology Unit, Emergency Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyThe Neurology Unit, Emergency Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyThe Neurology Unit, Emergency Department, Guglielmo da Saliceto Hospital, Via Taverna 39, 29121 Piacenza, ItalyIntroduction: Pediatric-onset multiple sclerosis (POMS) is characterized by high inflammatory disease activity. Our aim was to describe the treatment sequencing and report the impact highly effective disease-modifying treatment (HET) had on disease activity. Materials and Methods: Five consecutive patients with POMS were administered HET following lower efficacy drug or as initial therapy. Data on treatment sequencing, relapses and MRIs were collected during the follow-up. Results: Our patients had an average age of 13.8 years (range 9–17) at diagnosis and 13.4 years (range 9–16) at disease onset, and 2/5 (40%) POMS were female. The pre-treatment average annualized relapse rate was 1.6 (range 0.8–2.8), and the average follow-up length was 5 years (range 3–7). A total of 2/5 (40%) patients were stable on HET at initial therapy, and 3/5 (60%) required an escalation to more aggressive treatment, even if two of them had been put on HET as initial treatment. Four out of five patients (80%) had No Evidence of Disease Activity-3 status (NEDA-3) at an average follow-up of 3 years (range 2–5). Conclusion: It has been observed that in a recent time period all the cases had prompt diagnosis, early HET or escalation to HET with a good outcome in 80% of the cases.https://www.mdpi.com/2227-9067/9/11/1698pediatric onset multiple sclerosisPOMShighly effective treatmentsdisease-modifying drugsDMD |
| spellingShingle | Paolo Immovilli Paola De Mitri Veronica Bazzurri Stefano Vollaro Nicola Morelli Giacomo Biasucci Fabiola Magnifico Elena Marchesi Maria Lara Lombardelli Lorenza Gelati Donata Guidetti The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series Children pediatric onset multiple sclerosis POMS highly effective treatments disease-modifying drugs DMD |
| title | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
| title_full | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
| title_fullStr | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
| title_full_unstemmed | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
| title_short | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
| title_sort | impact of highly effective treatment in pediatric onset multiple sclerosis a case series |
| topic | pediatric onset multiple sclerosis POMS highly effective treatments disease-modifying drugs DMD |
| url | https://www.mdpi.com/2227-9067/9/11/1698 |
| work_keys_str_mv | AT paoloimmovilli theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT paolademitri theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT veronicabazzurri theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT stefanovollaro theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT nicolamorelli theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT giacomobiasucci theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT fabiolamagnifico theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT elenamarchesi theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT marialaralombardelli theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT lorenzagelati theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT donataguidetti theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT paoloimmovilli impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT paolademitri impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT veronicabazzurri impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT stefanovollaro impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT nicolamorelli impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT giacomobiasucci impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT fabiolamagnifico impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT elenamarchesi impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT marialaralombardelli impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT lorenzagelati impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT donataguidetti impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries |